ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

THN391 has the potential to be a first-in-class antibody that can block fibrin-mediated neuroinflammation without affecting coagulation pathways, and recently completed a phase 1ba trial in ...